0
Summaries for Patients |

Therapy to Prevent Stroke in Patients with Atrial Fibrillation FREE

[+] Article and Author Information

The summary below is from the full report titled “Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis.” It is in the 5 October 1999 issue of Annals of Internal Medicine (volume 131, pages 492-501). The authors are R.G. Hart, O. Benavente, R. McBride, and L.A. Pearce.


Ann Intern Med. 1999;131(7):492. doi:10.7326/0003-4819-131-7-199910050-00042
Text Size: A A A

What is the problem and what is known about it so far?

Atrial fibrillation is a kind of irregular heart rhythm. People with atrial fibrillation sometimes develop blood clots in their hearts. These clots can lead to stroke if the blood clots travel from the heart to the brain. Strokes are the neurologic problems, such as weakness or difficulty with speech, that result when brain tissue does not get enough blood. Antithrombotic medicines like warfarin or aspirin make the blood take longer to clot. These medicines can therefore prevent stroke in many people with atrial fibrillation. But doctors are sometimes reluctant to prescribe and patients can be reluctant to take these medications because they can lead to bleeding complications like bleeding ulcers or bleeding into the brain.

Why did the researchers do this particular study?

In recent years, different researchers have conducted 16 separate studies of antithrombotic medications for atrial fibrillation. The present researchers combined the data from these previous studies to better estimate the ability of these medications to prevent stroke and their likelihood of causing bleeding complications for patients with atrial fibrillation.

Who was studied?

In the 16 studies that were analyzed, there were a total of 9874 patients.

How was the study done?

Using computers, the researchers searched the medical literature to identify all studies of antithrombotic medications to prevent stroke for patients with atrial fibrillation. They included only randomized, controlled trials where patients received warfarin, aspirin, or no treatment. In a randomized, controlled trial, each patient has an equal chance of receiving one of the treatments. Studies are designed like this when it really is not clear that one treatment is better than another or better than no treatment at all. Using a statistical method called meta-analysis, the researchers combined the findings of the 16 separate studies.

What did the researchers find?

Warfarin and aspirin reduced the chances of stroke for patients with atrial fibrillation. Warfarin prevented more strokes than aspirin. Major bleeding complications did not outweigh these benefits.

What were the limitations of the study?

Combining the results of separate studies can be misleading, especially if the studies are very different from each other.

What are the implications of the study?

Physicians should prescribe antithrombotic medications to most patients with atrial fibrillation, except when particular patients have conditions that put them at high risk for bleeding complications. The choice between warfarin and aspirin depends on the inherent risk for stroke: Patients with atrial fibrillation who have the highest stroke risk benefit most from warfarin.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)